Richard Edelson

Q: What Schools Are Affiliated With Richard Edelson

Richard Edelson is affiliated with the following schools: Yale University, Rockefeller University

Richard Edelson's AcademicInfluence.com Rankings

Richard Edelson

Medical

#1250

World Rank

#1570

Historical Rank

Dermatology

#41

World Rank

#55

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Richard Edelson Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Richard Edelson is the Anthony Brady Professor of Dermatology at the Yale School of Medicine. He is a past director of the Yale Cancer Center, and an elected fellow of both the American Society for Clinical Investigation and the Association of American Physicians. He is known for his research discoveries in non-Hodgkins lymphoma, particularly his early career introduction of the disease category concept of Cutaneous T Cell Lymphoma , and his discovery of extracorporeal photochemotherapy as an immunotherapy for cancer, transplant reactions and autoimmunity.

(See a Problem?)

Richard Edelson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. (1987) (1087)
Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. (1975) (609)
Reactivity of Langerhans cells with hybridoma antibody. (1981) (543)
The Sézary syndrome: a malignant proliferation of helper T cells. (1976) (442)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) (423)
Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles (2006) (401)
Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants. (1980) (320)
Genomic landscape of cutaneous T cell lymphoma (2015) (315)
Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. (2005) (261)
Cutaneous T cell lymphoma: characterization by monoclonal antibodies. (1981) (237)
Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. (1992) (228)
Preferential cutaneous infiltration by neoplastic thymus-derived lymphocytes. Morphologic and functional studies. (1974) (228)
Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. (1990) (151)
Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. (1989) (148)
Cutaneous T-cell lymphoma: neoplasm of T cells with helper activity. (1979) (140)
The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. (2002) (138)
Induction of human tumor‐loaded dendritic cells (2001) (135)
Immunoelectron microscopic identification of Langerhans cells using a new antigenic marker. (1982) (122)
Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. (2000) (110)
Cutaneous T Cell Lymphoma (2001) (109)
Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. (2011) (106)
Identification of subpopulations of mononuclear cells in cutaneous infiltrates. I. Differentiation between B cells, T cells, and histiocytes. (1973) (106)
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). (1997) (102)
The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. (1996) (101)
Superantigenic staphylococcal exotoxins induce T-cell proliferation in the presence of Langerhans cells or class II-bearing keratinocytes and stimulate keratinocytes to produce T-cell-activating cytokines. (1994) (101)
Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. (1990) (99)
Light-activated drugs. (1988) (96)
Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. (1994) (95)
Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome. (1975) (94)
Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. (1989) (93)
Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. (1991) (91)
Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. (1992) (91)
Skin-selective lymphocyte homing mechanisms in the pathogenesis of leukemic cutaneous T-cell lymphoma. (1993) (89)
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. (2006) (87)
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. (1995) (86)
Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. (1974) (85)
A human leukemia cell with both B and T cell surface receptors. (1974) (83)
Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. (2010) (83)
Cutaneous T cell lymphoma: the helping hand of dendritic cells. (2001) (81)
CELL MEMBRANE DNA: A NEW TARGET FOR PSORALEN PHOTOADDUCT FORMATION (1990) (81)
Induction of lymphocyte differentiation by epidermal cultures. (1981) (80)
Monoclonal antibodies to DNA modified by 8-methoxypsoralen and ultraviolet A light. (1985) (79)
Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen (2014) (78)
Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. (1979) (77)
Photopheresis for the treatment of cutaneous T-cell lymphoma. (1995) (76)
Morphologic and functional properties of the atypical T lymphocytes of the Sezary syndrome. (1974) (76)
Photopheresis: a new therapeutic concept. (1989) (75)
Transimmunization, a novel approach for tumor immunotherapy. (2002) (74)
Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. (2014) (72)
The immunologic function of skin. (1985) (71)
Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma. (2006) (70)
Characterization of immature T cell subpopulations in neonatal blood. (1984) (70)
Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigens. (1982) (68)
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. (1996) (68)
Thymopoietin-like substance in human skin. (1983) (68)
The balance between immunity and tolerance: The role of Langerhans cells (2009) (65)
Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor (1998) (63)
A MALIGNANT PROLIFERATION OF HELPER T CELLS (1976) (60)
Kaposi's sarcoma following chemotherapy for testicular cancer in a homosexual man: demonstration of cytomegalovirus RNA in sarcoma cells. (1982) (58)
Photopheresis: present and future aspects. (1991) (56)
Characterization of immature T cell subpopulations in neonatal blood. (1984) (56)
Transimmunization for cutaneous T cell lymphoma: A phase I study (2006) (53)
FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma (2008) (51)
Cutaneous T-cell lymphomas: clues of a skin-thymus interaction. (1976) (51)
Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results. (1995) (49)
In situ identification of Langerhans cells in the dermal infiltrate of cutaneous T cell lymphoma. (1982) (48)
Photopheresis: a Clinically Relevant Immunobiologic Response Modifier (1991) (47)
Cutaneous T‐cell lymphoma (1976) (47)
Effects of Retinoids on the Immune System1 (1985) (46)
Rapid and sensitive analysis of 8-methoxypsoralen in plasma. (1988) (46)
Monoclonal antibody 4F2 reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative state. (1984) (46)
Transimmunization and the evolution of extracorporeal photochemotherapy. (2002) (44)
Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. (2014) (44)
CD30(+) cutaneous lymphoma in association with atopic eczema. (2004) (44)
Extracorporeal photochemotherapy induces bona fide immunogenic cell death (2019) (42)
Comparison of Synthetic Psoralen Derivatives and 8‐MOP in the Inhibition of Lymphocyte Proliferation a (1985) (42)
Enhanced Stimulation of Anti‐Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen (2011) (40)
Photoactivated 8‐methoxypsoralen treatment causes a peptide‐dependent increase in antigen display by transformed lymphocytes (1998) (40)
Application of a multiprobe RNase protection assay and junctional sequences to define V beta gene diversity in Sezary syndrome. (1992) (39)
Selective killing of T lymphocytes by phototoxic liposomes. (1987) (39)
Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. (2016) (39)
Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). (1989) (39)
Cytogenetic studies and clinical implications in patients with Sézary syndrome (1976) (38)
INTERACTION OF T CELLS WITH THE EPIDERMIS (1982) (38)
Correlations of unique clinical, immunotypic, and histologic findings in cutaneous gamma/delta T-cell lymphoma. (1992) (37)
Treatment of cutaneous T cell lymphoma. (1990) (37)
In situ study of T‐cell subpopulations in cutaneous T‐cell lymphoma: Diagnostic criteria (1984) (37)
Reversible Resistance to Apoptosis in Cutaneous T Cell Lymphoma (2001) (37)
Clonal chromosomal abnormalities in cutaneous T-cell lymphoma. (1987) (36)
A lymphocyte cell surface heat shock protein homologous to the endoplasmic reticulum chaperone, immunoglobulin heavy chain binding protein BIP (1997) (36)
Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. (2012) (36)
Dual genotype in cutaneous T cell lymphoma: immunoglobulin gene rearrangement in clonal T cell malignancy. (1988) (35)
Photopheresis for T cell mediated diseases. (1988) (33)
Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. (2018) (32)
Phototherapy and photopharmacology. (1985) (32)
WAVELENGTH DEPENDENCE FOR AMT CROSSLINKING OF pBR322 DNA (1984) (31)
The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma (2001) (30)
Cutaneous T cell lymphoma. (1980) (30)
National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. (2015) (30)
Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity* (2015) (30)
High-performance liquid chromotography analysis of 8-methoxypsoralen monoadducts and crosslinks in lymphocytes and keratinocytes. (1991) (29)
Patterns of cell proliferation and cell migration in the Sézary syndrome. (1981) (29)
Ocular findings in cutaneous T-cell lymphoma. (1991) (28)
Differentiation between B cells, T cells, and histiocytes in melanocytic lesions: primary and metastatic melanoma and halo and giant pigmented nevi. (1975) (28)
Langerhans cells: mediators of immunity and tolerance. (2006) (27)
THYMOPOIETIN-LIKE SUBSTANCE IN HUMAN SKIN (1982) (27)
Platelet P-selectin initiates cross-presentation and dendritic cell differentiation in blood monocytes (2020) (27)
Increased surface expression of class I MHC molecules on immunogenic cells derived from the xenogenization of P815 mastocytoma cells with 8-methoxypsoralen and long-wavelength ultraviolet radiation. (1995) (26)
INHIBITION OF ANTI‐SKIN ALLOGRAFT IMMUNITY INDUCED BY INFUSIONS WITH PHOTOINACTIVATED EFFECTOR T LYMPHOCYTES—THE CONGENIC MODEL (1991) (26)
Optimization of Stability, Encapsulation, Release, and Cross-Priming of Tumor Antigen-Containing PLGA Nanoparticles (2012) (25)
Formation and removal of 8-MOP-DNA photoadducts in keratinocytes: effects of calcium concentration and retinoids. (1990) (25)
Photopheresis for Rheumatoid Arthritis a (1991) (24)
Integrins alpha4beta7 and alphaEbeta7 are expressed on epidermotropic T cells in cutaneous T cell lymphoma and spongiotic dermatitis. (1999) (24)
Antithymocyte globulin in the management of cutaneous T cell lymphoma. (1979) (24)
American council on ECP (ACE): Why now? (2018) (24)
The kinetics of Sézary cell production. (1979) (23)
Transimmunization: the science catches up to the clinical success. (2002) (23)
Sézary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis. (1999) (23)
INHIBITORY EFFECT OF 8‐METHOXYPSORALEN PLUS ULTRAVIOLET‐A ON INTERLEUKIN‐1 PRODUCTION BY MURINE KERATINOCYTES (1991) (23)
Round cells of the epidermis: clues from studies on neoplastic lymphocytes of cutaneous T cell lymphoma. (1980) (23)
Photoactivatable antisense DNA: suppression of ampicillin resistance in normally resistant Escherichia coli. (1991) (22)
Antigen‐Specific Tolerance Induced by Autoimmunization with Photoinactivated Syngeneic Effector Cells a (1991) (22)
Pathogenesis of cutaneous T-cell lymphoma. (1985) (22)
Repair of 8-MOP photoadducts in human lymphocytes. (1990) (22)
Activation of GILZ gene by photoactivated 8-methoxypsoralen: potential role of immunoregulatory dendritic cells in extracorporeal photochemotherapy. (2014) (22)
Internalization and acidification of insulin by activated human lymphocytes (1984) (22)
Endocrine, Metabolic and Immunologic Functions of Keratinocytes (1989) (21)
Integrin‐driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy (2014) (21)
Extracorporeal photopheresis. (1984) (20)
Pemphigus--decoding the cellular language of cutaneous autoimmunity. (2000) (20)
The effects of gilvocarcin V and ultraviolet radiation on pBR322 DNA and lymphocytes. (1988) (19)
Immunology of cutaneous T-cell lymphoma. (1991) (19)
Effect of monochromatic UVA light and 8-methoxypsoralen on human lymphocyte response to mitogen. (1984) (19)
Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading (2005) (19)
Normal numbers of phenotypic helper, suppressor, and total T cell populations in psoriasis vulgaris: quantitation by monoclonal antibodies. (1981) (19)
The Role of Cytokines in the Pathophysiology of T cell Mediated Skin Disease (1987) (18)
P-Glycoprotein Expression and Multidrug Resistance in Cutaneous T-cell Lymphoma (2000) (18)
Biochemical characterization of a differentiation antigen shared by human epidermal langerhans cells and cortical thymocytes. (1982) (18)
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. (2003) (18)
The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy. (2004) (17)
Comparison of lymphocyte function after isolation by ficoll-hypaque flotation or elutriation. (1979) (17)
DEFINING THE MALIGNANT POTENTIAL OF THE GIANT PIGMENTED NEVUS (1976) (16)
Extracorporeal photochemotherapy: indications, methodology, safety aspects, side effects and long-term results. (1989) (16)
Monoclonal Antibodies for Clinical Investigation of Human T Lymphocytes (1983) (16)
Cutaneous T-cell lymphoma: pathogenesis and treatment. (2000) (16)
Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization (2002) (14)
Two varieties of Sézary syndrome, both bearing T-cell markers. (1973) (14)
HPLC ANALYSIS OF 4′,5′‐MONOADDUCT FORMATION IN CALF THYMUS DNA and SYNTHETIC POLYNUCLEOTIDES TREATED WITH UVA and 8‐METHOXYPSORALEN (1985) (14)
Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate. (1993) (14)
Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. (2016) (13)
Quantitation of psoralen photoadducts in DNA isolated from lymphocytes treated with 8-methoxypsoralen and ultraviolet A radiation (extracorporeal photopheresis). (1986) (13)
Recent advances in the cutaneous T cell lymphomas. (1977) (13)
Cutaneous T cell Lymphoma (1987) (13)
The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. (1994) (12)
Retinoid augmentation of bioactive interleukin‐1 production by murine keratinocytes (1992) (12)
INDUCTION OF A CELL‐TRANSFERABLE SUPPRESSION OF ALLOREACTIVITY BY PHOTODAMAGED LYMPHOCYTES (1992) (12)
Immunology and the Skin Current Concepts (1988) (12)
Use of Orthoclone monoclonal antibodies in the study of selected dermatologic conditions. (1981) (12)
Lymphoproliferative disease of granular lymphocytes. (1995) (11)
DNA ASSOCIATED WITH THE CELL MEMBRANE IS INVOLVED IN THE INHIBITION OF THE SKIN REJECTION RESPONSE INDUCED BY INFUSIONS OF PHOTODAMAGED ALLOREACTIVE CELLS THAT MEDIATE REJECTION OF SKIN ALLOGRAFT (1984) (11)
Receptor-mediated photo-cytotoxicity: synthesis of a photoactivatable psoralen derivative conjugated to insulin. (1986) (11)
Spread of antibiotic-resistant bacteria from acne patients to personal contacts-a problem beyond the skin? (1997) (11)
Suppression of anti-skin-allograft response by photodamaged effector cells--the modulating effects of prednisolone and cyclophosphamide. (1992) (11)
Ex vivo dendritic cell generation-A critical comparison of current approaches. (2019) (11)
Cutaneous T-cell lymphoma: a model for selective immunotherapy. (1998) (11)
Cardiogenic shock due to progression of cutaneous T-cell lymphoma. (1994) (11)
Identification of a thymopoietin like substance in epidermal cells from normal human skin (1982) (10)
Preparation and characterization of biotinylated psoralen. (1988) (10)
Clinical evolution of cutaneous T cell lymphoma in a patient with antibodies to human T-lymphotropic virus type I. (1987) (9)
Induction of an immature T-cell phenotype in malignant helper T cells by cocultivation with epidermal cell cultures. (1987) (9)
Preparation and characterization of blotinylated psoralen (1988) (9)
Reactivity of lupus erythematosus antibodies with leukemic helper T cells. (1978) (9)
Cutaneous T-cell lymphomas. (1983) (9)
Current Concepts of the Immunobiology and Immunotherapy of Cutaneous T Cell Lymphoma: Insights Gained through Cross-talk between the Clinic and the Bench (2003) (9)
T‐cell responses in photoimmune therapy (1995) (9)
Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer (2020) (8)
Interaction of T‐lymphocytes with the epidermis: immunopathological studies (1983) (8)
Quantification of methoxsalen-DNA adducts with specific antibodies. (1986) (8)
BE-2 antigen: appearance in activation and long-term growth of T cells. (1990) (8)
Biopolymer nanoparticles as antigen delivery vehicles for immunotherapy of head and neck squamous cell carcinoma (HNSCC) (2008) (7)
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. (2019) (7)
Neoplastic human T-cells capable of responding to multiple human alloantigens. (1980) (7)
Pathogenesis of T cell lymphoma of skin. (1983) (7)
The Delivery of Phototoxic Drugs to Selected Cells a (1985) (7)
Induction of functional empty class I major histocompatibility complex glycoproteins by photoactivated 8-methoxypsoralen. (1996) (7)
New therapies for cutaneous T-cell lymphoma. (1987) (7)
Cutaneous T-cell lymphoma. (2004) (7)
Inhibition of Antiskin Allograft Immunity Induced by Infusions with Photoinactivated Effector T Lymphocytes (PET Cells). Is In Vivo Cell Transferrable? (1991) (7)
Photopheresis therapy of cutaneous T cell lymphoma. (1988) (7)
Endocytosis of the TCR/CD3 complex and the class-I major histocompatibility complex in a human T cell line. (1991) (7)
Peripheral blood of patients with cutaneous T‐cell lymphoma: studies using monoclonal antibodies (1983) (7)
Outsmarting cutaneous T-cell lymphoma cells by decoding the language they speak: focusing past and present insights on future prospects. (2010) (6)
Development of Immunogenic Tumor-Loaded Dendritic Cells Through Physical Perturbation and Apoptotic Cell Loading (2008) (6)
Regulation of immunity by ultraviolet radiation and photosensitized reactions. (1994) (6)
The skin and T-cell differentiation. (1980) (6)
Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma. (2004) (6)
Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions (2020) (6)
MODULATION OF 8‐METHOXYPSORALEN‐DNA PHOTOADDUCT FORMATION BY CELL DIFFERENTIATION, MITOGENIC STIMULATION AND PHORBOL ESTER EXPOSURE IN MURINE T LYMPHOCYTES (1993) (5)
DNA ASSOCIATED WITH THE CELL MEMBRANE IS INVOLVED IN THE INHIBITION OF THE SKIN REJECTION RESPONSE INDUCED BY INFUSIONS OF PHOTODAMAGED ALLOREACTIVE CELLS THAT MEDIATE REJECTION OF SKIN ALLOGRAFT (1984) (5)
Nonmelanoma skin cancer, melanomas, warts, and viral oncogenesis. (1984) (5)
The diagnostic use of monoclonal antibodies in a variety of dermatologic conditions. (1983) (5)
Recognition of immature T-cell phenotypes in neonatal blood using monoclonal antibodies. (1983) (4)
Tumor-associated antigen is expressed on lymphocytes from patients with acquired immunodeficiency syndrome. (1986) (4)
Extracorporeal photochemotherapy for CTCL. (1990) (4)
Monoclonal Antibodies: Powerful New Tools for the Clinician (1982) (4)
MEMBRANE MARKERS OF LYMPHOCYTES IN LYMPHOMAS, MELANOMA AND LUPUS ERYTHEMATOSUS (1976) (4)
Other experimental observations. (1980) (4)
Antigenic modulation of pan-T-cell and T-cell subset-specific markers. (1983) (3)
Locomotion of T cells from patients with cutaneous T-cell lymphoma (Sézary syndrome and mycosis fungoides). (1980) (3)
Monoclonal antibodies: powerful new tools for the clinician. (1982) (3)
Extracorporeal photopheresis. (1984) (3)
Antigen and clone-specific immunoregulation (1991) (3)
Rapid Production of Physiologic Dendritic Cells (phDC) for Immunotherapy. (2020) (3)
Malignant tumors of the skin (1999) (3)
Phototoxic liposomes coupled to an antibody that alone cannot modulate its cell-surface antigen kill selected target cells (2005) (3)
Improved generation of anti-tumor immunity by antigen dose limitation (2007) (2)
Concanavalin‐A‐binding Proteins on the Surface of Human Malignant and Normal Lymphocytes (1979) (2)
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. (2008) (2)
Longitudinal study of surface antigen pattern in cutaneous T-cell lymphomas (1984) (2)
Dohi memorial lecture. Cutaneous T cell lymphoma. (1987) (2)
Quantification of 8-MOP Photoadducts in Lymphocytes (1991) (1)
Photopheresis: A New Approach to the Management of T-Cell Mediated Disorders (1991) (1)
Photoactivation of a Psoralen Derivative Conjugated to Insulin (1987) (1)
Quantifying in vivo murine antigen-specific T cell responses without requirement for prior knowledge of antigen identity. (2017) (1)
Effect of Prednisolone and Cyclophosphamide on Inhibition of the Response to Alloantigen Induced by Treatment with Photoinactivated Effector T Cells (PET Cells) (1991) (1)
2159 Total skin electron beam therapy(TSEBT) followed by adjuvant psoralen/ultraviolet A light (PUVA) in the management of patients with T1 and T2 cutaneous T-cell lymphoma (CTCL) (1996) (1)
Combination chemotherapy for advanced cutaneous T-cell lymphomas. (1980) (1)
Expression of integrin α4β7 on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis (1998) (1)
Partnering with skin to outsmart cancer: following leads provided by tumor-specific T cells. (2016) (1)
Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL] (1994) (1)
733 Potent immunogenic cell death (ICD) caused by UVA-Activated 8-Methoxypsoralen (8-MOPA) (2019) (1)
Cutaneous T cell lymphoma : basic and clinically relevant biology (2001) (1)
Aaron Lerner's Legacy at Yale University. (2007) (1)
Delivery of photoreactive psoralen derivatives to specific biological targets (1986) (1)
A Unique Case of Allogeneic Fat Grafting Between Brothers (2016) (1)
Sustained complete remission of skin disease in advanced CTCL (1989) (1)
Cancer Issue: Yale Cancer Center: Past, Present, and Future (2006) (1)
The influence of extracorporeal photopheresis (ECP) in addition to total skin electron (TSE) therapy on disease-free and cause-specific survival in patients with erythrodermic (T4) mycosis fungoides (MF) and the sezary syndrome (1998) (1)
275 Experimental ECP initiation of selective anti-tumor immunity (2016) (0)
99% circulating tumor cells with 90% accuracy Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to (2013) (0)
Immunoprotection against tumor-specific class I-associated T lymphoma antigens (1998) (0)
Reactivity of Langerhans cells with hybridoma antibody (delayed hypersensitivity/monoclonal antibody/epidermis/antigen presentation/thymocyte antigen) (2016) (0)
469 Experimental T cells immunotherapy by tumor-loaded ECP-generated dendritic antigen presenting cells (2016) (0)
Immunotherapy for Cutaneous T-Cell Lymphoma (2013) (0)
Steven R. Kohn (1943–1994) (1994) (0)
Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy (1994) (0)
Inhibition ofAntiskin Allograft Immunity Induced byInfusions withPhotoinactivated Effector TLymphocytes (PETCells) (1989) (0)
Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models (2022) (0)
Detection of Immunogenic Cell Death in Tumor Vaccination Mouse Model. (2020) (0)
111 Role of platelets in the differentiation of monocytes into dendritic cell-like antigen presenting cells (2018) (0)
08:40: Immunotherapy for Head and Neck Carcinoma with Nanoparticles (2007) (0)
Adjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT). (1993) (0)
vaccine cellular and their use for the treatment of malignant, solid tumors (1994) (0)
B.A.D. Investigative Group Meeting, Keele, September, 1982 (1983) (0)
Primary Care in Dermatology. (1979) (0)
616 UV-induced somatic mutations elicit a functional T cell response and tumor regression in BRAFV600E, CDKN2A-/-, PTEN-/- melanoma model (2016) (0)
Preparation of T-cells and T-cell membranes, suitable for the prevention and treatment of autoimmune diseases. (1989) (0)
Transimmunization for immunotherapy of head and neck squamous cell carcinoma (HNSCC) (2008) (0)
PHOTOPHERESIS : CLINICAL AND MECHANISTIC STUDIES (1996) (0)
A clinico-histopathologic atlas. (1980) (0)
Dendritic cell immunotherapy in malignancies (2007) (0)
Method for inducing an immune response selectively suppressed. (2002) (0)
Cutaneous T cell lymphoma: Current practices in blood assessment and the utility of T-cell receptor V β chain restriction (2016) (0)
The utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT] (1994) (0)
Specific modulation of the immune system. (1993) (0)
Abstract 3188: Transimmunization prevents recurrence and reprograms the immune milieu in a mouse model of ovarian cancer (2019) (0)
United States Patent ( 19 ) Edelson ( 54 ) METHOD FOR EXTERNALLY TREATING THE BLOOD (2017) (0)
Changing the Wound Healing Landscape — Offloading Stress , Aiding Stem Cells (2014) (0)
Control 0f the Immune Response by the Major Histocompatibility Compleχ (2011) (0)
Modulation of the immune system by means of psoralens, which are activated by visible light (1994) (0)
Outsmarting CTCL Cells by Decoding the Language They Speak: Focusing Past and Present Insights on Future Prospects (2014) (0)
Neville Kirsch (1911-1991) (1993) (0)
Response: validity of evidence demonstrating efficacy of extracorporeal photochemotherapy (2011) (0)
Photoactivated 8-methoxypsoralen (8-MOPa)-induced augmentation of the MHC class I antigen processing pathway (1998) (0)
A Murine T-Cell Lymphoma Model Showing Protection Against Tumor Development and Treatment of Established Disease (1994) (0)
Optimization of Stability, Encapsulation, Release, and Cross-Priming of Tumor Antigen-Containing PLGA Nanoparticles (2012) (0)
Yale Cancer Center: Past, Present, and Future (2006) (0)
Autoregulation of the Immune Response in Autoimmune Disease and Cardiac Transplantation by Photoinactivated Autologous Lymphocytes (1991) (0)
Specific immune modulation (1993) (0)
Optimizing extracorporeal photopheresis-induced monocyte-to-dendritic cell conversion for immunotherapy of solid tumours (2008) (0)
alloantigens Neoplastic human T-cells capable of responding to multiple human (2011) (0)
2158 Management of patients with T4 cutaneous T-cell lymphoma(CTCL) with total skin electron beam therapy(TSEBT) and adjuvant extracorporeal photochemotherapy(ECP) (1996) (0)
031 Experimental therapeutic melanoma vaccination by ECP-generated dendritic cells (2016) (0)
l Clinical Investigation TOTAL SKIN ELECTRON BEAM THERAPY FOLLOWED BY ADJUVANT PSORALEN/ULTRAVIOLET-A LIGHT IN THE MANAGEMENT OF PATIENTS WITH Tl AND T2 CUTANEOUS T-CELL LYMPHOMA (MYCOSIS FUNGOIDES) (1997) (0)
Cancer immunotherapy Review Article (2006) (0)
223 CD4+ T cell-mediated anti-tumor immunity generated by vaccination with ECP-generated DC (2016) (0)
[Identification of the lymphomonocytic cells of tissue infiltrates by labeling of the specific membrane receptors with sheep erythrocytes]. (1975) (0)
Cancer immunotherapy: From promise to practice (2008) (0)

This paper list is powered by the following services:

Other Resources About Richard Edelson

en.wikipedia.org

What Schools Are Affiliated With Richard Edelson?

Richard Edelson is affiliated with the following schools: